# A 24-wk Dose Ranging Study to Evaluate the Efficacy and Safety of 4 Doses of a New PDE4 Inhibitor in Patients With COPD

> **NCT02986321** · PHASE2 · COMPLETED · sponsor: **Chiesi Farmaceutici S.p.A.** · enrollment: 1130 (actual)

## Conditions studied

- Chronic Obstructive Pulmonary Disease

## Interventions

- **DRUG:** CHF6001
- **DRUG:** Budesonide
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02986321
- **Lead sponsor:** Chiesi Farmaceutici S.p.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-12-15
- **Primary completion:** 2017-10-04
- **Final completion:** 2018-01-09
- **Target enrollment:** 1130 (ACTUAL)
- **Last updated:** 2019-01-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02986321

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02986321, "A 24-wk Dose Ranging Study to Evaluate the Efficacy and Safety of 4 Doses of a New PDE4 Inhibitor in Patients With COPD". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02986321. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*